Results 121 to 130 of about 68,100 (329)

Exosomal cell-to-cell transmission of alpha synuclein oligomers

open access: yesMolecular Neurodegeneration, 2012
Background Aggregation of alpha-synuclein (αsyn) and resulting cytotoxicity is a hallmark of sporadic and familial Parkinson’s disease (PD) as well as dementia with Lewy bodies, with recent evidence implicating oligomeric and pre-fibrillar forms of αsyn ...
Danzer Karin M   +7 more
doaj   +1 more source

Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.

open access: yes, 2019
Parkinson's disease (PD) is characterized by the presence of α-synuclein aggregates known as Lewy bodies and Lewy neurites, whose formation is linked to disease development. The causal relation between α-synuclein aggregates and PD is not well understood.
Anichtchik, O.   +12 more
core   +1 more source

All Nanozyme‐Based Cascade Reactions for Biomedical Applications: from Self‐Cascading Nanozyme to Immobilized Cascade Nanozyme

open access: yesAdvanced Science, EarlyView.
This review introduces the development and classification of all‐nanozyme cascade reaction systems, highlighting mechanistic insights and research methods for understanding catalytic features and design principles. It provides detailed classifications, surveys recent applications in biosensing and therapy, and discusses the challenges that all‐nanozyme
Caixia Zhu   +4 more
wiley   +1 more source

Disrupting Lipid Raft Microdomains to Block Polyploid Giant Cancer Cell Budding and Enhance Radiotherapy Response

open access: yesAdvanced Science, EarlyView.
Radiation induces polyploid giant cancer cells (PGCCs) that regenerate tumors through virus‐like budding. This process depends on a SNCG–FLOT2–CHMP4B signaling axis functioning in lipid raft microdomains. Disrupting these domains using statins or anti‐PCSK9 antibodies blocks PGCC budding, suppresses tumor repopulation, and enhances radiotherapy ...
Zheng Deng   +20 more
wiley   +1 more source

Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease

open access: yesFrontiers in Neuroscience, 2018
Alpha-synuclein (non A4 component of amyloid precursor, SNCA, NM_000345.3) plays a central role in the pathogenesis of Parkinson's disease (PD) and related Lewy body disorders such as Parkinson's disease dementia, Lewy body dementia, and multiple system ...
Desiree A. Piper   +2 more
doaj   +1 more source

Hyperglycemia aggravates decrease in alpha-synuclein expression in a middle cerebral artery occlusion model [PDF]

open access: diamond, 2018
Ju-Bin Kang   +7 more
openalex   +1 more source

Structural Basis of the Membrane Association by the Conserved RocS Membrane‐Targeting Sequence in Streptococcus

open access: yesAdvanced Science, EarlyView.
Chromosome segregation in Streptococcus pneumoniae depends on RocS, a bitopic protein whose membrane‐anchoring mechanisms were unclear. Using NMR and AFM, this study reveals that the widely conserved RocS anchor binds to membranes via a conserved kink‐helix motif which inserts into lipid nanodomains.
Ana Álvarez‐Mena   +11 more
wiley   +1 more source

Antibody‐Empowered Nanomedicine for Precise Biomedical Applications

open access: yesAdvanced Science, EarlyView.
This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen   +7 more
wiley   +1 more source

Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration

open access: yesAdvanced Science, EarlyView.
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy